z-logo
Premium
‘Rational use of high‐flow therapy in infants with bronchiolitis. What do the latest trials tell us?’ A Paediatric Research in Emergency Departments International Collaborative perspective
Author(s) -
O'Brien Sharon,
Craig Simon,
Babl Franz E,
Borland Meredith L,
Oakley Ed,
Dalziel Stuart R
Publication year - 2019
Publication title -
journal of paediatrics and child health
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.631
H-Index - 76
eISSN - 1440-1754
pISSN - 1034-4810
DOI - 10.1111/jpc.14496
Subject(s) - medicine , bronchiolitis , context (archaeology) , cochrane library , intensive care medicine , systematic review , medline , cinahl , pediatrics , clinical trial , randomized controlled trial , oxygen therapy , emergency medicine , psychological intervention , nursing , psychiatry , surgery , paleontology , political science , respiratory system , law , biology
Bronchiolitis is the most common reason for infants to be hospitalised. Over the past decade, the use of high‐flow nasal cannulae (HFNC) therapy has increased markedly and it is now utilised not only in the intensive care unit setting but in general paediatric wards and emergency departments. The aim of this systematic review was to summarise and critique the current evidence‐base for the use of HFNC in infants with bronchiolitis. We searched Ovid Medline, OvidEmbase, PubMed, Cinahl, Cochrane Library, Cochrane Database of Systematic Reviews and Cochrane Central Register of Controlled Trials for systematic reviews and randomised controlled trials of HFNC therapy in infants with bronchiolitis from 1 January 2000 to 27 June 2018. We identified four randomised controlled trials ( n = 1891) of HFNC in infants with bronchiolitis: three of these studies involved infants treated in emergency departments and inpatient paediatric wards in Spain, Australia and New Zealand, and one study involved infants treated in paediatric intensive care units in France. The findings of this review suggest that HFNC should be used as a rescue treatment for hypoxaemic infants who have not responded to standard sub nasal oxygen therapy. The use of HFNC for work of breathing in the absence of hypoxaemia, and severe disease, is not currently supported by the evidence, and should only be considered in the context of an appropriate research trial.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here